Cibotercept is a fusion protein commercialized by Keros Therapeutics, with a leading Phase II program in Pulmonary Arterial Hypertension.

Pulmonary hypertension (PH) is a chronic, life-threatening condition involving high blood pressure in the arteries of the ...

If you're quickly ascending in altitude, your body may have trouble absorbing oxygen, which can lead to hypertension and ...

Treating PAH patient-derived blood vessel cells with calcitriol reduced vitamin D receptor deficiency and suppressed their ...

In the wake of Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study of pulmonary arterial hypertension, the company’s stock (NASDAQ:KROS) has crumpled after a year’s ...

Rx, a leading digital medicine and biomarker company driving healthcare through pulmonary innovation, today announced that it ...

Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR).

Rising blood levels of inflammatory marker neutrophil-to-lymphocyte ratio are linked to poorer outcomes with chronic kidney ...

The Mini Nutritional Assessment was viable for assessing nutritional status and predicting mortality outcomes in patients ...

- Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy ...

Chronic High Blood Pressure During Pregnancy ... This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading ...

A study reveals that weight loss can lead to significant healthcare savings, with 7% savings for a 5% BMI reduction and 30% ...